Cancer News

The latest in diagnostics and treatment

As a practice dedicated to the constant exploration of effective treatment for cancer, VCI aims to be your source for news on the latest breakthroughs. Please keep this page as a bookmark and check back regularly. Because one of the most important aspects of fighting cancer is knowing all you can.

World Cancer News

FDA approves new type of therapy to treat advanced urothelial cancer (12/19/2019)

Today, the U.S. Food and Drug Administration granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers. Padcev is indicated for the treatment of adult patients with locally... Continue Reading

FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma (12/05/2019)

Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib; BeiGene USA) for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy. Zanubrutinib is a small molecule inhibitor of Bruton tyrosine... Continue Reading

Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) compared Chemotherapy in Advanced Non-Small Cell Lung Cancer (11/29/2019)

The Opdivo plus low-dose Yervoy immunotherapy combination improved long-term survival for patients with advanced non-small cell lung cancer (NSCLCC) across PD-L1 expression levels. (3) Both Opdivo and Yervoy are effective for the treatment of many cancers including NSCLC. These drugs are designed to help the immune system recognize and fight cancer. Opdivo belongs to a class of medicines... Continue Reading

Alunbrig Continues to Demonstrate Superiority in the First – Line After Two Years of Follow-Up for ALK + NSCLC (11/27/2019)

Updated data released 11/2019 from the Phase 3 ALTA-1L clinical trial evaluating Alunbrig (brigatinib) versus Xalkori (crizotinib) in patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor demonstrate that with 25 months of follow up Alunbrig continues to demonstrate overall and intracranial effectiveness compared... Continue Reading

PARP Inhibitor + Avastin Delays Cancer Progression When Used as Initial Treatment for Ovarian Cancer (10/09/2019)

Maintenance therapy with the PARP inhibitor Lynparza (olaparib) added to Avastin (bevacizumab) resulted in a significant and clinically meaningful delay in cancer progression in patients with advanced stage III-IV ovarian cancer  according to the results of the phase 3 PAOLA-1/ENGOT-ov25 study presented at the European Society for Medical Oncology (ESMO) Congress 2019. (1) About Lynparza... Continue Reading

E-Cigarette Smoke Causes Lung Cancer in Mice (10/08/2019)

Exposure to e-cigarette smoke caused mice to develop lung cancer, a new study finds. Published online October 7 in Proceedings of National Academy of Sciences (PNAS), the study found that 9 of 40 mice (22.5 percent) exposed to e-cigarette smoke with nicotine for 54 weeks developed lung adenocarcinomas. None of the 20 mice from the study... Continue Reading

Tagrisso Improves Overall Survival in EGFR-Mutation Positive NSCLC (10/04/2019)

Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA clinical trial presented at the ESMO Congress in Oct 2019. (1,2) the median overall survival with osimertinib was 38.6 months compared to 31.8... Continue Reading

Addition of Avastin to Tarceva Doesn’t Improve Outcome in EGF-Positive NSCLC (09/27/2019)

Progression-free survival (PFS) rates with erlotinib therapy plus bevacizumab for EGFR-positive non–small-cell lung cancer (NSCLC) were not superior to those seen with erlotinib monotherapy, according to findings from a phase 2 clinical trial. In the study, Thomas E. Stinchcombe, MD, Duke Cancer Institute, Durham, North Carolina, and colleagues sought to determine whether adding bevacizumab to standard... Continue Reading

Monitoring of Symptoms More Important Than Blood Counts in Polycythemia Vera (09/24/2019)

A recent study supports what individuals with polycythemia vera (PV) have known for years. PV associated symptoms are underappreciated by doctors and don’t necessarily correlate with blood counts levels. Individuals with PV can experience symptoms of fatigue, itching, weakness, headaches and other symptoms despite being on medication. All too often physicians don’t appreciate the severity... Continue Reading

Ask the Expert About Treatment of Advanced Colon Cancer (09/23/2019)

Dr. Tanios Bekaii- Saab, MD, Program Head Mayo Clinic answered questions about management of advanced colo-rectal cancer CancerConnect and The Personalized Medicine Foundation were pleased to provide patients and caregivers the opportunity to ask questions about the management of advanced colo-rectal cancer with Dr Tanios Bekaii-Saab, MD FACP Head-Mayo Clinic Gastrointestinal Cancer Program & Director... Continue Reading